This inventor holds 6 USPTO granted patents. Top assignees: Betagene, Inc., The University of Texas System, Urocor, Inc.. Active years: 1999-2001.
Company Filing History:
2 out of 4 
2 out of 5,630 
2 out of 13 Years Active: 1999-2001
Title: Anice E Thigpen: Innovator in Recombinant Protein Production and Diabetes Treatment
Introduction
Anice E Thigpen is an accomplished inventor based in Dallas, TX, with a remarkable portfolio of six patents. Her work focuses on pioneering methods related to recombinant expression of proteins and novel approaches for diabetes treatment. Thigpen's innovative contributions have had a significant impact on the biotechnology field and medical therapies.
Latest Patents
Anice Thigpen's latest patents showcase her expertise in biotechnology. One significant patent pertains to the "Recombinant expression of proteins from secretory cell lines." This invention outlines methods for producing heterologous polypeptides through engineered secretory cell lines. The innovation revolves around utilizing host cell machinery to generate valuable proteins while minimizing endogenous polypeptide production. Additionally, this patent describes high-level expression methodologies, large-scale protein production tactics, and viral delivery systems for in vivo disease treatment.
Another pivotal patent focuses on "Methods and compositions relating to no-mediated cytotoxicity." It involves innovative strategies for treating diabetes using free radicals. Thigpen's research demonstrates that manganese superoxide dismutase (MnSOD) can mitigate cytokine-induced cell damage, highlighting the potential for engineering cell lines as islet surrogates for transplant therapy in diabetes management. Her findings also indicate the role of fatty acids in β-cell dysfunction in adipogenic diabetes, providing avenues for ameliorating this disorder.
Career Highlights
Anice Thigpen has established a formidable career, contributing her skills to organizations like Betagene, Inc. and the University of Texas System. Through her roles at these institutions, she has advanced her research and innovation efforts, building a strong foundation in biotechnology and therapeutic applications. Her work not only emphasizes scientific advancement but also aims at improving patient outcomes in chronic diseases.
Collaborations
Throughout her career, Anice Thigpen has collaborated with notable professionals in her field, including Christopher B Newgard and Karl D Normington. These collaborations have enhanced her research efforts and facilitated the development of groundbreaking technologies that address pressing health issues, particularly in diabetes.
Conclusion
Anice E Thigpen exemplifies the pioneering spirit of innovation within the biotech industry. Her significant contributions to the fields of protein production and diabetes treatment highlight the importance of scientific research in addressing health challenges. With a track record of successful patents and collaborations, Thigpen continues to inspire future advancements in medical biotechnology, leaving a lasting impact on the industry.